Root, AA;
Wong, AY;
Ghebremichael-Weldeselassie, Y;
Smeeth, L;
Bhaskaran, K;
Evans, SJ;
Brauer, R;
... Douglas, I; + view all
(2016)
Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs.
British Journal of Clinical Pharmacology
, 82
(2)
pp. 512-521.
10.1111/bcp.12983.
Preview |
Text (Published version of record)
Root_et_al-Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs VoR.pdf Download (593kB) | Preview |
![[thumbnail of Supplementary data: Appendices S1 to S9]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text (Supplementary data: Appendices S1 to S9)
Root_et_al-Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs - Supplementary data.pdf Access restricted to UCL open access staff Download (318kB) |
Abstract
AIM: Some previous studies suggest a long term association between clarithromycin use and cardiovascular events. This study investigates this association for clarithromycin given as part of Helicobacter pylori treatment (HPT). METHODS: Our source population was the Clinical Practice Research Datalink (CPRD), a UK primary care database. We conducted a self-controlled case series (SCCS), a case-time-control study (CTC) and a propensity score adjusted cohort study comparing the rate of cardiovascular events in the 3 years after exposure to HPT containing clarithromycin with exposure to clarithromycin free HPT. Outcomes were first incident myocardial infarction, arrhythmia and stroke. For the cohort analysis we included secondary outcomes all-cause and cardiovascular mortality. RESULTS: 28,552 patients were included in the cohort. The incidence rate ratio of first MI within a year of exposure to HPT containing clarithromycin was 1.07 (95% CI: 0.85-1.34, p = 0.58) and within 90 days was 1.43 (95% CI: 0.99-2.09 p = 0.057) in the SCCS analysis. CTC and cohort results were consistent with these findings. CONCLUSIONS: There was some evidence for a short term association for first MI but none for a long term association for any outcome.
| Type: | Article |
|---|---|
| Title: | Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bcp.12983 |
| Publisher version: | http://dx.doi.org/10.1111/bcp.12983 |
| Language: | English |
| Additional information: | Copyright © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | adverse drug reaction, cardiovascular disease, clarithromycin, pharmacoepidemiology |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1488425 |
Archive Staff Only
 |
View Item |
